- The disease
- Acute respiratory failure is a condition in which the lungs cannot provide enough oxygen to the body or cannot remove carbon dioxide effectively, often requiring supplemental oxygen or mechanical breathing support. It is a common cause of admission to intensive care units and emergency departments. Weaning failure refers to the inability to successfully remove a patient from mechanical ventilation, which prolongs hospital stays and increases complications. Both conditions carry substantial morbidity and mortality.
- What the asset is trying to do
- Optiflow is a nasal high flow (NHF) oxygen delivery device manufactured by Fisher and Paykel Healthcare. It delivers humidified, heated oxygen at higher flow rates than conventional nasal cannulas or face masks, which can help flush carbon dioxide from the upper airway, reduce the effort of breathing, and improve oxygenation. Unlike standard oxygen masks, NHF therapy uses a purpose-designed nasal interface and an integrated humidification system to make continuous high-flow gas delivery tolerable for patients.
- What the trial is measuring, and why it matters
- The completed NCT02107183 trial compared NHF therapy using Optiflow against a Venturi mask in patients being weaned from mechanical ventilation, with weaning failure as the key outcome of interest (per ClinicalTrials.gov NCT02107183). NCT03223948 examined NHF in acute respiratory failure settings (per ClinicalTrials.gov NCT03223948). NCT03883555 assessed NHF against non-invasive ventilation (NIV) in acute hypercapnic cardiogenic pulmonary edema in the emergency department (per ClinicalTrials.gov NCT03883555). These endpoints reflect clinically meaningful outcomes such as reintubation rates, oxygenation, and the need to escalate respiratory support.
- Efficacy benchmarks in this setting
- In studies of post-extubation oxygen support, standard oxygen therapy has been associated with reintubation rates varying by patient risk profile; Hernandez et al (JAMA, 2016) reported a reintubation rate of 22.8% with conventional oxygen versus 9.1% with high-flow nasal cannula in low-risk extubation patients. For weaning failure more broadly, reported rates with conventional approaches depend heavily on patient population and ventilation duration. The trials linked to Optiflow are comparator-controlled studies; early-stage or single-arm figures from device studies are not statistically comparable to these referenced benchmarks.